Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay Registry

Long-term daily practice data on patient-reported benefits of dupilumab for atopic dermatitis (AD) remains limited.

Source: Journal of the American Academy of Dermatology - April 21, 2024 Category: Dermatology Authors: Junfen Zhang, Celeste M. Boesjes, Laura Loman, Esm é Kamphuis, Margreet L.E. Romeijn, Lotte S. Spekhorst, Inge Haeck, Lian F. van der Gang, Coco C. Dekkers, Lisa P. van der Rijst, Albert J. Oosting, Paula van Lumig, Anneke M.T. van Lynden-van Nes, Ron A. Source Type: research